Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00375635
Other study ID # MBD2006
Secondary ID
Status Recruiting
Phase N/A
First received September 12, 2006
Last updated September 12, 2006
Start date March 2006
Est. completion date October 2006

Study information

Verified date September 2006
Source Rigshospitalet, Denmark
Contact Mette B Damholt, MD,Ph.d.
Phone +45 35453545
Email damholt@dadlnet.dk
Is FDA regulated No
Health authority Denmark: Ethics Committee
Study type Interventional

Clinical Trial Summary

The aim of this study is to examine removal of protein bound uremic substances by mFPSA in chronic hemodialysis patients. mFPSA is an extracorporal blood purification system developed for detoxification in acute liver failure by removal of protein bound as well as water soluble substances.


Description:

Measurements of uremic protein bound substances before and after mFPSA and a preceding routine hemodialysis session.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date October 2006
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Over the age of 18

- Anuria

- Chronic hemodialysis dependence

Exclusion Criteria:

- No present history of bleeding episodes

- Cardiac diseases

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Procedure:
mFPSA treatment


Locations

Country Name City State
Denmark Rigshospitalet Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Blood pressure
Primary Safety serological parameters
Primary Concentrations of protein bound uremic toxins
Secondary Bleeding episodes
See also
  Status Clinical Trial Phase
Not yet recruiting NCT00577967 - Gabapentin - A Solution to Uremic Pruritus? N/A
Completed NCT01583309 - Effects of Convective Therapies in Dialysis Patients Phase 3
Completed NCT03437538 - Reduction Ratio and Clearance During Hemodialysis With MCO-filter Compared to HDF With Standard High-flux Filter N/A
Completed NCT00649298 - A Clinical Trial of IntensiVE Dialysis Phase 4
Completed NCT05750875 - Gabapentin Versus Loratadine in Uremic Pruritus Phase 4
Recruiting NCT01408797 - Clonal Deletion on Living-Relative Donor Kidney Transplantation Phase 1/Phase 2
Completed NCT01267760 - Clinical and Biochemical Effects of Multipass Hemodialysis Phase 2
Recruiting NCT05076318 - Dysregulated Urea-synthesis at Terminal Uremia N/A
Completed NCT05899283 - A Comparative Study of Two Kinds of Hemodialysis Filters N/A
Completed NCT04768309 - Impact of Intestinal Microbiota on Uremic Toxins Productions N/A
Not yet recruiting NCT05386433 - Paxlovid in the Treatment of COVID-19 Patients With Uremia Early Phase 1
Completed NCT01391884 - Elimination of Incretin Hormones in Patients With Severe Kidney Failure N/A
Completed NCT00442819 - Uremic Pruritus, Cytokines and Polymethylmethacrylate Artificial Kidney Phase 4
Not yet recruiting NCT02266238 - Stenosis of Arteria-Venous Fistula in Maintenance Hemodialysis Patients: Early Intervention Trial N/A
Recruiting NCT01766895 - Long-term Follow Up of Viral Hepatitis in Uremic Patients in Taiwan
Completed NCT00388648 - Very Low Protein Diet or Dialysis in Uremic Elderly? Phase 4
Withdrawn NCT03416192 - 12 Weeks of Hemodialysis With Medium Cut-Off Filter Compared to Hemodiafiltration With Standard High-flux Filter. N/A
Recruiting NCT02606955 - Probing the Dry Weight by Bioimpedance: The Resistance Stabilization Test N/A
Recruiting NCT02446535 - Probing the Dry Weight (DW) by Bioimpedance (BIA): Which is the Gold Standard Between Clinical DW and BIA DW? N/A
Completed NCT02050139 - L-Cysteine in Peritoneal Dialysis Phase 2